E2 ModerateWeak / uncertainPEM not requiredCase-ControlPeer-reviewedReviewed
Monospot and VP1 tests in chronic fatigue syndrome and major depression.
Lynch, S P, Seth, R V, Main, J · Journal of the Royal Society of Medicine · 1992 · DOI
Quick Summary
This study tested whether two blood tests (Monospot and VP1) could help identify ME/CFS by comparing 34 ME/CFS patients with 34 people who had depression. While some patients tested positive for VP1 virus markers, the tests could not reliably tell the two groups apart, and results were inconsistent when patients were retested six months later.
Why It Matters
Understanding whether viral markers like VP1 distinguish ME/CFS from other conditions such as depression is crucial for developing diagnostic criteria and identifying disease mechanisms. This early study helps clarify why simple viral serology tests have not proven useful for ME/CFS diagnosis, informing more targeted biomarker research strategies.
Observed Findings
- Eleven of 34 CFS patients tested VP1 positive initially, compared with 7 of 34 depression controls
- Four CFS patients but zero depression controls tested Monospot positive initially
- No patient tested positive on both Monospot and VP1 simultaneously
- Of 8 retested VP1-positive CFS patients, 4 remained positive; of 4 retested depression controls, none remained VP1 positive
- No patient who retested remained Monospot positive at the 6-month follow-up
Inferred Conclusions
- Monospot and VP1 tests have poor discriminatory ability between CFS and major depression
- VP1 positivity may show greater persistence in CFS patients than in depression controls
- These serological tests lack sufficient predictive validity for clinical screening purposes in distinguishing between these conditions
Remaining Questions
- What is the clinical significance of VP1 persistence in CFS patients versus transient positivity in depression controls?
- Are there other viral markers or detection methods that might better distinguish ME/CFS from other conditions?
- Do VP1-positive and VP1-negative CFS subgroups differ in symptoms, disease course, or other biomarkers?
What This Study Does Not Prove
This study does not prove that viral infections play no role in ME/CFS; it only shows that Monospot and VP1 antigen tests are not reliable diagnostic tools. The findings do not establish whether VP1 presence represents active infection, past exposure, or a coincidental finding. Absence of test discrimination between groups does not exclude the possibility that viral factors contribute to disease pathogenesis in subsets of patients.
Tags
Symptom:Fatigue
Biomarker:AutoantibodiesBlood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
Metadata
- DOI
- 10.1177/014107689208500909
- PMID
- 1433120
- Review status
- Editor reviewed
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 12 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.